Skip to Content

What are the side effects of Ilumya?

Medically reviewed by Last updated on Jun 19, 2018.

Official Answer


The most common side effects of Ilumya are:

  • upper respiratory infections (14% Ilumya vs. 12% placebo),
  • injection site reactions (3% Ilumya vs. 2% placebo), and
  • diarrhea (2% Ilumya vs. 1% placebo).

Upper respiratory infections include nasopharyngitis (common cold), upper respiratory tract infection, viral upper respiratory tract infection, and pharyngitis. Injection site reactions may involve itching, pain, redness, swelling, bruising, hematoma (a solid blood clot under the skin), and bleeding.

Ilumya may also cause serious side effects such as allergic reactions with angioedema (swelling in the lower layers of the skin, often in the face, tongue, throat, arms or legs), urticaria (hives), and infections.

Before starting Ilumya, patients should be evaluated for tuberculosis.

In March, 2018 the FDA approved Ilumya (tildrakizumab-asmn), a humanized interleukin-23 p19 subunit antagonist (anti-IL-23p19) monoclonal antibody for moderate-to-severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy (ultraviolet or UV light).


Related Medical Questions

Drug Information

Related Support Groups